TP53 and non-small cell lung carcinoma: Moreover, we found that IC2 had a significantly higher epigenetic age but there was no difference regarding chronological age between both subgroups, congruent with previous observations in NSCLC [23], where a higher epigenetic age was able to emulate the malignant potential of tumors with a high mutational load or decisive driver mutations including TP53 [23].